• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Kintara Therapeutics Inc. (Amendment)

    2/7/22 1:26:53 PM ET
    $KTRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KTRA alert in real time by email
    SC 13G/A 1 caro20220202_sc13ga.htm SCHEDULE 13G/A caro20220202_sc13ga.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Kintara Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    49720K101

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐Rule 13d-1(b)

    ☒Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

     

     

     

    SCHEDULE 13G

    (Amendment No. 2)

     

    CUSIP NO. 49720K101

     

    1

    NAME OF REPORTING PERSON

     

    Carolyn A. Pilkiewicz

    2

    CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP

     

    (a)

    (b) X*

    3

    SEC USE ONLY

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    20,223 

    6

    SHARED VOTING POWER

     

    1,150,067

    7

    SOLE DISPOSITIVE POWER

     

    20,223

    8

    SHARED DISPOSITIVE POWER

     

    1,150,067

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,170,290 **

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    2.41%***

    12

    TYPE OF REPORTING PERSON

     

    IN

     

    For purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, all shares of the common stock, $0.001 par value per share (the “Common Stock”) of Kintara Therapeutics, Inc. (the “Company”) beneficially owned by The Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001 (“FGPRT”) may be deemed to be beneficially owned by Carolyn A. Pilkiewicz and Michael B. DeGidio as Co-Trustees of FGPRT.

     

    * The reporting persons expressly disclaim (i) the existence of any group and (ii) beneficial ownership with respect to any shares other than the shares owned of record by such reporting person and as set forth below.

     

    ** This amount consists of: 1,170,290 shares of the Common Stock held by Mrs. Pilkiewicz, including 1,150,067 shares of Common Stock held by FGPRT of which Mrs. Pilkiewicz is a beneficiary and Co-Trustee and 20,223 shares of Common Stock held by Mrs. Pilkiewicz personally. Mrs. Pilkiewicz has shared voting and investment control of the securities held by FGPRT.

     

    *** Based on 48,535,338 shares of the Company’s Common Stock outstanding as of November 11, 2021.

     

     

     

     

     

    SCHEDULE 13G

    (Amendment No. 2)

     

    CUSIP NO. 49720K101

     

    1

    NAME OF REPORTING PERSON

     

    Michael B. DeGidio

    2

    CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP

     

    (a)

    (b) X*

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    4,601

    6

    SHARED VOTING POWER

     

    1,150,067

    7

    SOLE DISPOSITIVE POWER

     

    4,601

    8

    SHARED DISPOSITIVE POWER

     

    1,150,067

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,154,668 **

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    2.38%***

    12

    TYPE OF REPORTING PERSON

     

    IN

     

    * The reporting person expressly disclaims (i) the existence of any group and (ii) beneficial ownership with respect to any shares other than the shares owned of record by such reporting person. Mr. DeGidio is Co-Trustee of FGPRT, but is not a beneficiary and disclaims beneficial ownership of the securities held FGPRT. Mr. DeGidio expressly acknowledges that he individually neither holds any beneficial ownership, nor any pecuniary interest, in such FGPRT securities.

     

    ** This amount consists of: 1,154,668 shares of the Common Stock held by Mr. DeGidio, including 1,150,067 shares of Common Stock held by FGPRT of which Mr. DeGidio is a Co-Trustee and 4,601 shares of Common Stock held by Mr. DeGidio personally. Mr. DeGidio has shared voting and investment control of the securities held by FGPRT.

     

    *** Based on 48,535,338 shares of the Company’s Common Stock outstanding as of November 11, 2021.

     

     

     

     

    SCHEDULE 13G

    (Amendment No. 2)

     

    CUSIP NO. 49720K101

     

    1

    NAME OF REPORTING PERSON

     

    The Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

    2

    CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP

     

    (a)

    (b) X*

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    New Jersey

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,150,067

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,150,067

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,150,067

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    2.37%**

    12

    TYPE OF REPORTING PERSON

     

    OO

     

    * The reporting person expressly disclaims (i) the existence of any group and (ii) beneficial ownership with respect to any shares other than the shares owned of record by such reporting person. Mr. DeGidio expressly acknowledges that he individually neither holds any beneficial ownership, nor any pecuniary interest, in such securities.

     

    ** Based on 48,535,338 shares of the Company’s Common Stock outstanding as of November 11, 2021.

     

     

     

     

    SCHEDULE 13G

    (Amendment No. 2)

     

    Item 1(a).

     

    Name of Issuer:

         
       

    Kintara Therapeutics, Inc. (the “Company”).

         

    Item 1(b).

     

    Address of Issuer’s Principal Executive Offices:

       

    12707 High Bluff Dr., Suite 200, San Diego, CA 92130

         

    Item 2(a) and (b).

     

    Name of Person Filing and Address of Principal Business or Office or, if none, Residence:

         
       

    Carolyn Pilkiewicz

       

    The Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

       

    Michael B. DeGidio

       

    3 Davenport Drive

       

    Princeton Junction, NJ 08550

         

    Item 2(c).

     

    Citizenship:

         
       

    Carolyn Pilkiewicz is a citizen of the United States.

       

    The Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001 was organized under the laws of the State of New Jersey.

       

    Michael B. DeGidio is a citizen of the United States.

     

    Item 2(d).

     

    Title of Class of Securities:

         
       

    Common Stock

         

    Item 2(e).

     

    CUSIP No.:

         
       

    49720K101

         

    Item 3.

     

    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

             
     

    (a)

    ☐

    Broker or Dealer registered under Section 15 of the Act.

     

    (b)

    ☐

    Bank as defined in Section 3(a)(6) of the Act.

     

    (c)

    ☐

    Insurance Company as defined in Section 3(a)(19) of the Act.

     

    (d)

    ☐

    Investment company registered under Section 8 of the Investment Company Act of 1940.

     

    (e)

    ☐

    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

    (f)

    ☐

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

    (g)

    ☐

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

    (h)

    ☐

    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)

    ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940;

     

    (j)

    ☐

    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

     

    (k)

    ☐

    Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

     

     

    Item 4.

    Ownership:

             
       

    (a) Amount beneficially owned:    

             
       

    Carolyn Pilkiewicz

    -

    1,170,290 shares.

             
       

    This amount consists of: 1,170,290 shares of the Common Stock held by Mrs. Pilkiewicz, including 1,150,067 shares of Common Stock held by FGPRT of which Mrs. Pilkiewicz is a beneficiary and Co-Trustee and 20,223 shares of Common Stock held by Mrs. Pilkiewicz personally. Mrs. Pilkiewicz has shared voting and investment control of the securities held by FGPRT.

       
             
       

    The Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

    -

    1,150,067 shares.

             
       

    Michael B. DeGidio

    -

    1,154,668 shares

             
       

    This amount consists of: 1,154,668 shares of the Common Stock held by Mr. DeGidio, including 1,150,067 shares of Common Stock held by FGPRT of which Mr. DeGidio is a Co-Trustee and 4,601 shares of Common Stock held by Mr. DeGidio personally. Mr. DeGidio has shared voting and investment control of the securities held by FGPRT.

       
             
       

    (b) Percent of class:

             
       

    Carolyn Pilkiewicz

    -

    2.41%

       

    The Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

    -

    2.37%.

       

    Michael B. DeGidio

    -

    2.38%

             
       

    (c) Number of shares as to which the person has:

     

     

         

    (i) Sole power to vote or to direct the vote:

               
         

    Carolyn Pilkiewicz

    -

    20,223 shares.

         

    Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

    -

    -0- shares.

         

    Michael B. DeGidio

    -

    4,601 shares.

               
         

    (ii) Shared power to vote or to direct the vote:

               
         

    Carolyn Pilkiewicz

    -

    1,150,067 shares.

         

    Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

    -

    1,150,067 shares.

         

    Michael B. DeGidio

    -

    1,150,067 shares.

               
         

    (iii) Sole power to dispose or to direct the disposition of:

               
         

    Carolyn Pilkiewicz

    -

    20,223 shares.

         

    Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

    -

    -0- shares.

         

    Michael B. DeGidio

    -

    4,601 shares.

               
         

    (iv) Shared power to dispose or to direct the disposition of:

               
         

    Carolyn Pilkiewicz

    -

    1,150,067 shares.

         

    Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

    -

    1,150,067 shares.

         

    Michael B. DeGidio

    -

    1,150,067 shares.

     

    Item 5.

    Ownership of Five Percent or Less of a Class:

       
     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

     

     

     

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person:

       
     

    Not Applicable

       

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

       
     

    Not Applicable

       

    Item 8.

    Identification and Classification of Members of the Group:

       
     

    Not Applicable

       

    Item 9.

    Notice of Dissolution of Group:

       
     

    Not Applicable

       

    Item 10.

    Certification:

       
     

    By signing below each of Carolyn Pilkiewicz, Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001, and Michael B. DeGidio certifies that, to the best of such reporting person’s knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 7, 2022

     
         

    By:

    /S/ Carolyn Pilkiewicz

     
     

    Carolyn Pilkiewicz, Co-Trustee

     
         

    By:

    /S/ Michael B. DeGidio

     
     

    Michael B. DeGidio

     
         

    FRANK G. PILKIEWICZ REVOCABLE TRUST DTD 10-17-2001

     
         

    By:

    /S/ Carolyn Pilkiewicz

     
     

    Carolyn Pilkiewicz, Co-Trustee

     
         

    By:

    /S/ Michael B. DeGidio

     
     

    Michael B. DeGidio, Co-Trustee

     

     

     

     

     

    LIST OF EXHIBITS

     

         

    Exhibit No.

     

    Description

       

    99.1*

     

    Joint Filing Agreement (incorporated by reference to Exhibit 1 to the Schedule 13G filed by and among the Reporting Persons on November 16, 2020).

     

    * Previously filed.

     

     
    Get the next $KTRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KTRA

    DatePrice TargetRatingAnalyst
    1/20/2022$6.00 → $3.00Buy
    HC Wainwright & Co.
    9/30/2021$7.00 → $5.00Buy
    Aegis Capital
    9/28/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $KTRA
    Financials

    Live finance-specific insights

    See more
    • Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

      SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal fourth quarter ended June 30, 2024, and provided a corporate update. Recent Corporate Developments As previously disclosed, in April 2024 Kintara entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, w

      10/8/24 7:00:00 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results

      SAN DIEGO, May 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2024, and recent corporate developments. Recent Corporate Developments Announced that Kintara had entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, whereby Kayak Merge

      5/14/24 4:45:00 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

      TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA's accelerated approval pathway$31 million subscribed financing by TuHURA in connection with the merger agreement expected to provide cash runway into late 2025TuHURA's first-in-class bifunctional Antibody Drug Conjugates (ADCs) represents potential upside partnering opportunitiesCompanies are to hold a joint conference call and webcast today, Wednesday, April 3 at 8:30 AM ETSAN DIEGO and TAMPA, Fla., April 3, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara"), a bi

      4/3/24 7:00:00 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors

      SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm

      5/4/21 8:00:00 AM ET
      $KTRA
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Proactive news headlines including BetterLife Pharma, HempFusion Wellness, Pure Gold Mining, Mirasol Resources and OTC Markets Group

      New York, March 03, 2021 (GLOBE NEWSWIRE) -- - Medexus Pharmaceuticals Inc (CVE:MDP)  shares climb as Canaccord Genuity upgrades rating to Buy from Hold following fiscal 3Q results click here - BioPorto A/S  (CPH:BIOPOR) expects to complete its clinical study and submit a De Novo application to the US FDA for pediatric use of its NGAL kidney test this summer click here  - EVmo  Inc (OTCMKTS:YAYO) closes its controlling interest sale to Acuitas Group Holdings click here - Mountain Valley MD Holdings Inc (CSE:MVMD) (OTCQB:MVMDF) brings on Camargo Pharmaceutical Services to boost US FDA approval for Ivectsol click here - Alpine 4 Technologies Ltd (OTCQB:ALPP) appoi

      3/3/21 2:25:29 PM ET
      $KTRA
      $PHUN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      EDP Services
      Technology
    • Kintara Therapeutics Appoints Dr. Mario Lacouture to Scientific Advisory Board for Cutaneous Metastatic Breast Cancer

      SAN DIEGO, March 3, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Mario Lacouture, M.D. to the REM-001 Scientific Advisory Board with the initial focus in Cutaneous Metastatic Breast Cancer (CMBC). "We are pleased to welcome Dr. Lacouture to our CMBC focused Scientific Advisory Board as we prepare REM-001, our photodynamic therapy platform, for late-stage pivotal testing in this debilitating oncology indication," commented Saiid Zarrabian, Kintara's Chief Executive Officer. "We look forward to working closely with Dr. La

      3/3/21 8:00:00 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Scientific Officer Yamashita Dennis

      4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 9:12:33 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Patel Vijay claimed ownership of 7,999,557 shares (SEC Form 3)

      3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 8:50:14 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ng George K

      4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 8:47:13 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Kintara Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $3.00 from $6.00 previously

      1/20/22 5:37:53 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital reiterated coverage on Kintara Therapeutics with a new price target

      Aegis Capital reiterated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $5.00 from $7.00 previously

      9/30/21 9:44:25 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Kintara Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $6.00

      9/28/21 6:18:53 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Kintara Therapeutics Inc. (Amendment)

      SC 13G/A - Kintara Therapeutics, Inc. (0001498382) (Subject)

      2/13/23 4:29:24 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Kintara Therapeutics Inc.

      SC 13G - Kintara Therapeutics, Inc. (0001498382) (Subject)

      4/20/22 5:11:42 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Kintara Therapeutics Inc. (Amendment)

      SC 13G/A - Kintara Therapeutics, Inc. (0001498382) (Subject)

      2/7/22 1:26:53 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

      SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 16, 2024. Kintara announced today that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 18, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger

      10/16/24 12:54:00 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

      SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 17, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger (the "Merger") with TuHURA Biosciences, Inc. ("TuHURA"), with a new CUSIP number 898920 103.

      10/16/24 11:58:00 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

      SAN DIEGO, Oct. 15, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 14, 2024, regarding a record date for the issuance of the Contingent Value Rights ("CVRs") to stockholders of Kintara pursuant to the definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"). Kintara announced today that the CVRs will not be issued to stockholders of record of Kintara based on a record date of October 17, 2024, but rather will be issued stockholders of record of Kint

      10/15/24 4:15:00 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTRA
    SEC Filings

    See more
    • Kintara Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Leadership Update, Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Changes in Control of Registrant

      8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)

      10/21/24 8:30:25 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Kintara Therapeutics Inc.

      EFFECT - Kintara Therapeutics, Inc. (0001498382) (Filer)

      10/16/24 12:15:03 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kintara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)

      10/15/24 4:20:08 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care